Opinion|Videos|November 18, 2024
BCC Case Example: How Advanced Disease Requires Collaborative Care
Panelists discuss how a complex case of advanced basal cell carcinoma (BCC) demonstrates the necessity for collaborative care across multiple specialties, highlighting the importance of tailored treatment strategies and coordinated management to achieve the best possible patient outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5